This grant funds the creation, distribution, and assessment of evidence-based guidelines for managing dental pain (surgical and non-surgical) to reduce opioid prescriptions.
Food and Drug Administration has archived this opportunity.
Funder: Food and Drug Administration (FDA)
Due Dates: Archived (original deadline May 26, 2021)
Funding Amounts: Not specified; cooperative agreement funding for development and evaluation of clinical guidelines
Summary: Supports development, dissemination, implementation, and evaluation of evidence-based clinical practice guidelines for managing dental pain to reduce opioid prescribing.
Key Information: Funding opportunity is archived; targeted at a broad range of applicants including governments, nonprofits, academic institutions, and for-profit organizations.
This grant opportunity was issued by the Food and Drug Administration (FDA) under the Department of Health and Human Services to support the development of an evidence-based clinical practice guideline (CPG) for dental pain management, including both surgical and non-surgical pain. The initiative aligns with Section 3002 of the SUPPORT Act (signed into law in October 2018), which mandates the FDA Commissioner to develop opioid analgesic prescribing guidelines for acute pain treatment where none currently exist.
The FDA contracted the National Academies of Science, Engineering, and Medicine (NASEM) to create a framework for these guidelines. In December 2019, NASEM identified dental surgeries (such as third molar extraction) and dental pain as priority areas due to their high prevalence, the affected patient populations (notably adolescents and young adults), and existing evidence supporting nonopioid pain management strategies.
The grant aims to fund projects that will:
This effort is part of a broader public health strategy to reduce opioid prescriptions and improve pain management practices in dental care.